1921
Volume 96, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Dapsone is a bactericidal and bacteriostatic against , a causative agent of leprosy. Dapsone is also applied in a range of medical fields because of its anti-inflammatory and immunomodulatory effects. Dapsone hypersensitivity syndrome (DHS) is a rare yet serious adverse drug reaction (ADR) caused by dapsone involving multiple organs. We performed a systematic review of published articles describing dapsone-induced hypersensitivity syndrome, including all Chinese articles and the latest literature available in online databases published between October 2009 and October 2015. We determined the prevalence, clinical characteristics, and mortality rate of DHS. Importantly, we also summarized the recent advances in genetic testing allowing prediction of ADRs. In an initial systematic electronic search, we retrieved 191 articles. Subsequently, these articles were further filtered and ultimately 84 articles (60 Chinese case reports, 21 non-Chinese articles, and three epidemiological studies) were selected, which included 877 patients. The prevalence of DHS among Chinese patients was 1.5% with a fatality rate of 9.6%. Early withdrawal of dapsone and appropriate treatment reduced the fatality rate. Most importantly, genetic screening for the HLA-B*13:01 allele among high-risk populations showed a significant utility as a useful genetic marker to DHS. In conclusion, this review discusses the epidemiological and clinical characteristics of DHS among Chinese patients, which may help physicians to understand this syndrome.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0628
2017-05-03
2017-12-13
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/5/1014.html?itemId=/content/journals/10.4269/ajtmh.16-0628&mimeType=html&fmt=ahah

References

  1. Lowe J, , 1950. Treatment of leprosy with diamino-diphenylsulphone by mouth. Lancet 255: 145150.[Crossref]
  2. Richardus JH, Smith TC, , 1989. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr Rev 60: 267273.
  3. Lowe J, Smith M, , 1949. The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones. Int J Lepr 17: 181195.
  4. Alldy EJ, Barnes J, , 1951. Toxic effects of diaminodiphenylsulphone in the treatment of leprosy. Lancet 2: 205206.[Crossref]
  5. Puri AS, Gupta R, Ghoshal UC, Khan E, Aggarwal R, Naik SR, , 1995. Hepatic injury in sulfone syndrome: hepatitis or cholestasis? Indian J Gastroenterol 14: 20.
  6. Agrawal S, Agarwalla A, , 2005. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol 32: 883889.[Crossref]
  7. Lau G, , 1995. A fatal case of drug-induced multi-organ damage in a patient with Hansen's disease: dapsone syndrome or rifampicin toxicity? Forensic Sci Int 73: 109115.[Crossref]
  8. Sheen YS, Chu CY, Wang SH, Tsai TF, , 2009. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J Dermatolog Treat 20: 340343.[Crossref]
  9. Pandey B, Shrestha K, Lewis J, Hawksworth RA, Walker SL, , 2007. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. Trop Doct 37: 162163.[Crossref]
  10. Teo RYL, Tay YK, Tan CH, Ng V, Oh DC, , 2006. Presumed dapsone-induced drug hypersensitivity syndrome causing reversible hypersensitivity myocarditis and thyrotoxicosis. Ann Acad Med Singapore 35: 833836.
  11. Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, 3rd Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA, , 2002. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med 162: 921928.[Crossref]
  12. Prussick R, Shear NH, , 1996. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 35: 346349.[Crossref]
  13. Chalasani P, Baffoe-Bonnie H, Jurado RL, , 1994. Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. South Med J 87: 11451146.[Crossref]
  14. Zhang FR, Liu H, Irwanto A, Fu XA, Li Y, Yu GQ, Yu YX, Chen MF, Low HQ, Li JH, Bao FF, Foo JN, Bei JX, Jia XM, Liu J, Liany H, Wang N, Niu GY, Wang ZZ, Shi BQ, Tian HQ, Liu HX, Ma SS, Zhou Y, You JB, Yang Q, Wang C, Chu TS, Liu DC, Yu XL, Sun YH, Ning Y, Wei ZH, Chen SL, Chen XC, Zhang ZX, Liu YX, Pulit SL, Wu WB, Zheng ZY, Yang RD, Long H, Liu ZS, Wang JQ, Li M, Zhang LH, Wang H, Wang LM, Xiao P, Li JL, Huang ZM, Huang JX, Li Z, Liu J, Xiong L, Yang J, Wang XD, Yu DB, Lu XM, Zhou GZ, Yan LB, Shen JP, Zhang GC, Zeng YX, de Bakker PI, Chen SM, Liu JJ, , 2013. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 369: 16201628.[Crossref]
  15. Tian W, Shen J, Zhou M, Yan L, Zhang G, , 2012. Dapsone hypersensitivity syndrome among leprosy patients in China. Lepr Rev 83: 370377.
  16. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT, , 2008. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14: 13431350.[Crossref]
  17. Xu X, Yang R, Wu N, Zhong P, Ke Y, Zhou L, Yuan J, Li G, Huang H, Wu B, , 2009. Severe hypersensitivity dermatitis and liver dysfunction induced by occupational exposure to trichloroethylene. Ind Health 47: 107112.[Crossref]
  18. Lorenz M, Wozel G, Schmitt J, , 2012. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 92: 194199.[Crossref]
  19. Pirmohamed M, Ostrov DA, Park BK, , 2015. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J Allergy Clin Immunol 136: 236244.[Crossref]
  20. Rudolph MG, Stanfield RL, Wilson IA, , 2006. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24: 419466.[Crossref]
  21. Wei CY, Lee MT, Chen YT, , 2012. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet 21: R58R65.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0628
Loading
/content/journals/10.4269/ajtmh.16-0628
Loading

Data & Media loading...

  • Received : 01 Aug 2016
  • Accepted : 19 Dec 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error